ACADIA Pharmaceuticals, Inc. (ACAD)
19.73
-0.58
(-2.86%)
USD |
NASDAQ |
Oct 23, 16:00
19.72
-0.01
(-0.05%)
After-Hours: 20:00
ACADIA Pharmaceuticals Enterprise Value : 2.514B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 2.514B |
| October 22, 2026 | 2.613B |
| October 21, 2026 | 2.593B |
| October 20, 2026 | 2.636B |
| October 19, 2026 | 2.526B |
| October 16, 2026 | 2.409B |
| October 15, 2026 | 2.510B |
| October 14, 2026 | 2.431B |
| October 13, 2026 | 2.322B |
| October 12, 2026 | 2.458B |
| October 09, 2026 | 2.522B |
| October 08, 2026 | 2.488B |
| October 07, 2026 | 2.500B |
| October 06, 2026 | 2.515B |
| October 05, 2026 | 2.579B |
| October 02, 2026 | 2.551B |
| October 01, 2026 | 2.541B |
| September 30, 2026 | 2.586B |
| September 29, 2026 | 2.598B |
| September 28, 2026 | 2.651B |
| September 25, 2026 | 2.677B |
| September 24, 2026 | 2.935B |
| September 23, 2026 | 3.495B |
| September 22, 2026 | 3.663B |
| September 21, 2026 | 3.661B |
| Date | Value |
|---|---|
| September 18, 2026 | 3.815B |
| September 17, 2026 | 3.842B |
| September 16, 2026 | 3.858B |
| September 15, 2026 | 3.724B |
| September 14, 2026 | 3.854B |
| September 11, 2026 | 3.908B |
| September 10, 2026 | 3.892B |
| September 09, 2026 | 3.882B |
| September 08, 2026 | 3.865B |
| September 04, 2026 | 3.941B |
| September 03, 2026 | 3.913B |
| September 02, 2026 | 4.097B |
| September 01, 2026 | 4.090B |
| August 31, 2026 | 4.094B |
| August 28, 2026 | 4.128B |
| August 27, 2026 | 4.235B |
| August 26, 2026 | 4.209B |
| August 25, 2026 | 4.379B |
| August 24, 2026 | 4.221B |
| August 21, 2026 | 4.195B |
| August 20, 2026 | 4.116B |
| August 19, 2026 | 4.317B |
| August 18, 2026 | 4.312B |
| August 17, 2026 | 4.111B |
| August 14, 2026 | 3.978B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agios Pharmaceuticals, Inc. | 1.619B |
| Biogen, Inc. | 44.10B |
| Insmed, Inc. | 19.97B |
| Arcutis Biotherapeutics, Inc. | 3.794B |
| BioMarin Pharmaceutical, Inc. | 14.17B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 31.50M |
| Revenue (Quarterly) | 307.96M |
| Total Expenses (Quarterly) | 276.46M |
| EPS Diluted (Quarterly) | 0.1822 |
| Gross Profit Margin (Quarterly) | 90.81% |
| Profit Margin (Quarterly) | 10.23% |
| Earnings Yield | 11.25% |
| Operating Earnings Yield | 2.55% |
| Normalized Earnings Yield | 11.25 |